REFERENCES
4. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol 2020;22:iv1-iv96.
5. Park JS, Withers SS, Modiano JF, et al. Canine cancer immunotherapy studies: linking mouse and human. J Immunother Cancer 2016;4:97.
6. Chambers MR, Bentley RT, Crossman DK, et al. The one health consortium: design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in combination with a checkpoint inhibitor in canine patients with sporadic high grade gliomas. Front Surg 2020;7:59.
7. DeCordova S, Shastri A, Tsolaki AG, et al. Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma. Front Immunol 2020;11:1402.
8. Kijima N, Kanemura Y. Mouse models of glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane (AU): Codon Publications; 2017. p. 131-9.
9. Lenting K, Verhaak R, Ter Laan M, Wesseling P, Leenders W. Glioma: experimental models and reality. Acta Neuropathol 2017;133:263-82.
10. Miyai M, Tomita H, Soeda A, Yano H, Iwama T, Hara A. Current trends in mouse models of glioblastoma. J Neurooncol 2017;135:423-32.
11. Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 2007;334:197.
12. U.S. Department of Health and Human Services, FDA. Challenge and opportunity on the critical path to new medical technologies. March, 2004. Available from: https://www.who.int/intellectualproperty/documents/en/FDAproposals.pdf [Last accessed on 21 Oct 2021].
13. Alvarez CE. Naturally occurring cancers in dogs: insights for translational genetics and medicine. ILAR J 2014;55:16-45.
14. Koehler JW, Miller AD, Miller CR, et al. A revised diagnostic classification of canine glioma: towards validation of the canine glioma patient as a naturally occurring preclinical model for human glioma. J Neuropathol Exp Neurol 2018;77:1039-54.
15. Richards KL, Motsinger-Reif AA, Chen HW, et al. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Res 2013;73:5029-39.
16. Fenger JM, London CA, Kisseberth WC. Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology. ILAR J 2014;55:69-85.
17. Hicks J, Platt S, Kent M, Haley A. Canine brain tumours: a model for the human disease? Vet Comp Oncol 2017;15:252-72.
18. Priester WA, McKay FW. The occurrence of tumors in domestic animals. Natl Cancer Inst Monogr 1980;(54):1-210.
19. Snyder JM, Shofer FS, Winkle TJ, Massicotte C. Canine intracranial primary neoplasia: 173 cases (1986-2003). J Vet Intern Med 2006;20:20-75.
20. Miller AD, Miller CR, Rossmeisl JH. Canine primary intracranial cancer: a clinicopathologic and comparative review of glioma, meningioma, and choroid plexus tumors. Front Oncol 2019;9:1151.
21. Estevez-Ordonez D, Chagoya G, Salehani A, et al. Immunovirotherapy for the treatment of glioblastoma and other malignant gliomas. Neurosurg Clin N Am 2021;32:265-81.
22. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990;250:1262-6.
23. Friedman GK, Bernstock JD, Chen D, et al. Enhanced sensitivity of patient-derived pediatric high-grade brain tumor xenografts to oncolytic HSV-1 virotherapy correlates with nectin-1 expression. Sci Rep 2018;8:13930.
24. Nguyen HM, Guz-Montgomery K, Saha D. Oncolytic virus encoding a master pro-inflammatory cytokine interleukin 12 in cancer immunotherapy. Cells 2020;9:400.
25. Pavlin D, Cemazar M, Sersa G, Tozon N. IL-12 based gene therapy in veterinary medicine. J Transl Med 2012;10:234.
26. Omar NB, Bentley RT, Crossman DK, et al. Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas. Neurosurg Focus 2021;50:E5.
27. Goulart MR, Hlavaty SI, Chang YM, et al. Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells. Sci Rep 2019;9:3574.
28. Jackson K, Milner RJ, Doty A, et al. Analysis of canine myeloid-derived suppressor cells (MDSCs) utilizing fluorescence-activated cell sorting, RNA protection mediums to yield quality RNA for single-cell RNA sequencing. Vet Immunol Immunopathol 2021;231:110144.
29. Mason NJ, Coughlin CM, Overley B, et al. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther 2008;15:955-65.
30. Moreira ML, Dorneles EM, Soares RP, et al. Cross-reactivity of commercially available anti-human monoclonal antibodies with canine cytokines: establishment of a reliable panel to detect the functional profile of peripheral blood lymphocytes by intracytoplasmic staining. Acta Vet Scand 2015;57:51.
31. Rothe K, Bismarck D, Büttner M, Alber G, von Buttlar H. Canine peripheral blood CD4+CD8+ double-positive Tcell subpopulations exhibit distinct Tcell phenotypes and effector functions. Vet Immunol Immunopathol 2017;185:48-56.
32. Dalton MF, Stilwell JM, Krimer PM, Miller AD, Rissi DR. Clinicopathologic features, diagnosis, and characterization of the immune cell population in canine choroid plexus tumors. Front Vet Sci 2019;6:224.
33. Rissi DR, Porter BF, Boudreau CE, Krimer PM, Miller AD. Immunohistochemical characterization of immune cell infiltration in feline glioma. J Comp Pathol 2018;160:15-22.
34. Mason N, Bailey C, Piazza E, et al. Abstract 1693: Multi-national, multi-center collaboration to develop a novel gene expression tool for comparative translational immuno-oncology. Cancer Res 2021;81:1693.
35. Fraser AR, Bacci B, le Chevoir MA, Long SN. Epidermal growth factor receptor and Ki-67 expression in canine gliomas. Vet Pathol 2016;53:1131-7.
36. Pi Castro D, José-López R, Fernández Flores F, et al. Expression of FOXP3 in canine gliomas: immunohistochemical study of tumor-infiltrating regulatory lymphocytes. J Neuropathol Exp Neurol 2020;79:184-93.
37. Toedebusch R, Grodzki AC, Dickinson PJ, et al. Glioma-associated microglia/macrophages augment tumorigenicity in canine astrocytoma, a naturally occurring model of human glioma. Neurooncol Adv 2021;3:vdab062.
38. Filley A, Henriquez M, Bhowmik T, et al. Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas. J Neurooncol 2018;137:469-79.
39. Sloma EA, Creneti CT, Erb HN, Miller AD. Characterization of inflammatory changes associated with canine oligodendroglioma. J Comp Pathol 2015;153:92-100.
40. Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain tumor microenvironment and host state: implications for immunotherapy. Clin Cancer Res 2019;25:4202-10.
41. Bonaventura P, Shekarian T, Alcazer V, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol 2019;10:168.
42. Louie RJ, Perez MC, Jajja MR, et al. Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience. J Am Coll Surg 2019;228:644-9.
43. Andtbacka RHI, Collichio FA, Amatruda T, et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. JCO 2013;31:LBA9008.
44. Franke V, Berger DMS, Klop WMC, et al. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). Int J Cancer 2019;145:974-8.
45. Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 2017;170:1109-19.e10.
46. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010;17:718-30.
47. Benencia F, Courrèges MC, Conejo-García JR, et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005;12:789-802.
48. Reinert LS, Lopušná K, Winther H, et al. Sensing of HSV-1 by the cGAS-STING pathway in microglia orchestrates antiviral defence in the CNS. Nat Commun 2016;7:13348.
50. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015;14:642-62.
51. Nayak L, Molinaro AM, Peters K, et al. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. Clin Cancer Res 2021;27:1048-57.
52. Iorgulescu JB, Gokhale PC, Speranza MC, et al. Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma. Clin Cancer Res 2021;27:276-87.
53. Otvos B, Alban TJ, Grabowski MM, et al. Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome. Clin Cancer Res 2021;27:2038-49.
54. Chongsathidkiet P, Jackson C, Koyama S, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 2018;24:1459-68.
